For the quarter ending 2025-09-30, IDXG made $8,756,000 in revenue. $911,000 in net income. Net profit margin of 10.40%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue, net | 8,756,000 | 9,232,000 | 11,515,000 | 11,731,500 |
| Cost of revenue | 3,317,000 | 3,956,000 | 4,145,000 | 3,363,500 |
| Gross profit | 5,439,000 | 5,276,000 | 7,370,000 | 7,494,000 |
| Sales and marketing | 2,087,000 | 2,910,000 | 2,814,000 | 2,952,000 |
| Research and development | 150,000 | 173,000 | 177,000 | 165,500 |
| General and administrative | 2,057,000 | 2,661,000 | 2,550,000 | 2,403,500 |
| Total operating expenses | 4,294,000 | 5,744,000 | 5,541,000 | 5,521,000 |
| Operating income from continuing operations | 1,145,000 | -468,000 | 1,829,000 | 1,973,000 |
| Other expense, net | - | - | - | 35,000 |
| Note payable interest | 30,000 | 49,000 | 78,000 | 154,000 |
| Interest accretion expense | - | 0 | - | 9,000 |
| Other expense, net | -115,000 | -16,000 | 21,000 | - |
| Income from continuing operations before tax | 1,000,000 | -533,000 | 1,772,000 | 1,722,000 |
| (benefit) provision for income taxes | -11,000 | 0 | 18,000 | -2,000 |
| Income from continuing operations | 1,011,000 | -533,000 | 1,754,000 | 1,724,000 |
| Loss from discontinued operations, net of tax | -100,000 | -107,000 | -107,000 | -44,000 |
| Net income | 911,000 | -640,000 | 1,647,000 | 1,680,000 |
| Less adjustment for preferred stock deemed dividend | - | - | - | 116,000 |
| Net income attributable to common stockholders | - | - | - | 1,559,500 |
| Basic | 4,425,000 | 4,423,000 | 4,420,000 | -2,191,000 |
| Diluted | 27,695,000 | 4,423,000 | 27,704,000 | 3,455,000 |
| Net income (loss) per basic share of common stock | 0.21 | -0.14 | 0.37 | 0.33 |
| Net income (loss) per diluted share of common stock | 0.03 | -0.14 | 0.06 | -0.18 |
INTERPACE BIOSCIENCES, INC. (IDXG)
INTERPACE BIOSCIENCES, INC. (IDXG)